Milestone Pharmaceuticals (MIST) Gets a Buy from Piper Sandler
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst Edward Tenthoff has reiterated a Buy rating on Milestone Pharmaceuticals (MIST) with a price target of $7.00. Tenthoff, who specializes in the Healthcare sector, has an average return of 7.8% and a success rate of 40.96% on his stock recommendations. The analyst consensus for Milestone Pharmaceuticals is a Strong Buy, with a price target consensus of $7.25.
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Milestone Pharmaceuticals, with a price target of $7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Karyopharm Therapeutics. According to TipRanks, Tenthoff has an average return of 7.8% and a 40.96% success rate on recommended stocks.
Milestone Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $7.25.